Drug Name: RDC5
Company: Chronos Therapeutics
Location: United Kingdom
Website: http://www.chronostherapeutics.com
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease
Mechanism Type: Neuroprotection
Mechanism: RDC5 increases autophagy and protein turnover in cells. The approach also activated other pathways including the repair of DNA damage and the reduction of oxidative stress. Chronos has tested RDC5 in both a C. elegans SOD1 model and in SOD1 and TDP-43 mouse models. RDC5 was protective in the C. elegans model, showing a decreased toxicity and a reduced level of toxic protein aggregates.
U.S. Status for ALS: N/A

[1] A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers. ClinicalTrials.gov, 11 Mar 2014. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02016742.

Last updated March 9th, 2016

Share this: